Riyaz Basha

Riyaz Basha, PhD, is a Professor and Vice Chair for Research in the Department of Pediatrics at the Texas College of Osteopathic Medicine, University of North Texas Health Science Center. His research focuses on experimental therapeutics, cancer drug resistance, and health disparities, with a particular emphasis on developing targeted therapies for cancers like breast, pancreatic, and hepatocellular carcinoma.

Education: BS in Biology and Chemistry, MS in Molecular Physiology, and PhD in Neurobiology from Sri Venkateswara University, India.

Research Interests:
Dr. Basha’s lab targets molecular markers such as c-Met, Sp1 transcription factor, and survivin to enhance cancer therapy efficacy. Key projects include combining investigational agents with chemotherapies, genomic profiling for precision medicine, and collaborations with AI/ML experts to address disparities in cancer treatment. His work leverages preclinical models and clinical specimens to develop less toxic therapies.

Recent Trends in Articles:
Focus on immunotherapy (e.g., PD-1 targeting, cancer vaccines), molecular mechanisms of drug action (e.g., mithramycin, tolfenamic acid), and addressing health disparities in hepatocellular carcinoma and other malignancies. Computational studies (molecular docking, AI-driven drug design) are increasingly integral to his research.

Grants & Collaborations:
Principal/Co-Investigator in NIH-funded projects like the AIM-AHEAD Coordinating Center and Bridge2AI, focusing on translational research and health equity. Collaborates with institutions like Cook Children’s Medical Center and NCI-designated cancer centers.

Labs/Teams:
His lab integrates molecular biology, proteomics, and next-generation sequencing to study cancer biology and therapeutic resistance. Active in developing liquid biopsies and genomic biomarkers for personalized medicine.